Ozempic and Bowel Obstruction: Symptoms, Risks, and Legal Options

Bowel obstruction — also called intestinal obstruction — is one of the most dangerous injuries associated with GLP-1 receptor agonist drugs like Ozempic, Wegovy, and Mounjaro. Unlike gastroparesis, which involves slowed stomach emptying, bowel obstruction involves a physical blockage of the intestines that can become a life-threatening medical emergency requiring hospitalization and surgery. If you developed a bowel obstruction after taking a GLP-1 drug, understanding the medical and legal landscape is critical.

What Is a Bowel Obstruction?

A bowel obstruction occurs when the normal passage of food, fluids, and digestive contents through the intestines is blocked. The blockage can be partial (some material passes through) or complete (nothing passes through). Complete bowel obstructions are medical emergencies that require immediate treatment.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) categorizes intestinal obstructions based on their cause and location:

• Small bowel obstruction — blockage in the small intestine, which is the most common type
• Large bowel obstruction — blockage in the colon or rectum
• Intestinal pseudo-obstruction (ileus) — the intestines behave as if they are obstructed due to impaired motility, even though no physical blockage exists. This is particularly relevant to GLP-1 drug injuries, as the drugs’ mechanism of slowing gut motility can create functional obstruction.

Symptoms of Bowel Obstruction

Bowel obstruction symptoms typically develop rapidly and can escalate to emergency status within hours:

• Severe abdominal pain and cramping — often described as wave-like or colicky, corresponding to the intestines attempting to push contents past the obstruction
• Abdominal distension (swelling) — the abdomen becomes visibly swollen as gas and fluid accumulate behind the blockage
• Inability to pass gas or have a bowel movement — a hallmark sign of complete obstruction
• Nausea and vomiting — particularly severe with small bowel obstruction; vomiting may become feculent (containing fecal matter) in advanced cases
• Loss of appetite
• Rapid heart rate and fever — signs that the obstruction may be causing complications such as tissue death or infection

If you experience these symptoms, seek emergency medical care immediately. Untreated bowel obstruction can lead to:

• Intestinal ischemia — loss of blood supply to the affected segment, causing tissue death
• Intestinal perforation — a hole in the intestinal wall, allowing contents to leak into the abdominal cavity
• Peritonitis — a serious, life-threatening infection of the abdominal lining
• Sepsis — a systemic infection that can lead to organ failure and death

The Connection to GLP-1 Drugs

GLP-1 receptor agonists work by activating GLP-1 receptors throughout the gastrointestinal tract, which slows gut motility — the muscular contractions that move food through the digestive system. While this mechanism is intended to promote feelings of fullness and reduce food intake, it can have dangerous consequences:

How GLP-1 Drugs Cause Obstruction

1. Severe motility reduction — the drug slows intestinal contractions to the point that food and digestive contents cannot move through the intestines normally
2. Bezoar formation — undigested food can solidify into a mass (bezoar) that physically blocks the intestinal passage
3. Ileus (pseudo-obstruction) — the intestines become functionally paralyzed, mimicking a physical blockage
4. Interaction with adhesions — patients who have had prior abdominal surgery may have adhesions (scar tissue) that, combined with reduced motility from GLP-1 drugs, create conditions for obstruction

What the FDA Knows

The FDA’s adverse event database (FAERS) has received numerous reports of intestinal obstruction associated with GLP-1 receptor agonists. FDA safety communications have addressed gastrointestinal risks of semaglutide-based drugs, though plaintiffs in the litigation argue that warnings about the severity and frequency of bowel obstruction have been inadequate.

The current drug labels include gastrointestinal adverse event warnings, but the litigation contends that these warnings do not adequately convey the emergency nature and life-threatening potential of bowel obstruction, and that the manufacturers knew the risk was higher than what was disclosed.

Legal Claims for Bowel Obstruction

Bowel obstruction cases are among the most compelling in the GLP-1 MDL because of the severity and urgency of the injury. The legal claims assert:

• Failure to warn — the manufacturers did not adequately warn patients or prescribers about the risk and severity of bowel obstruction
• Defective design — the drug’s risk of causing bowel obstruction outweighs its benefits, or the manufacturer failed to design adequate safeguards (such as dose-adjustment protocols to mitigate motility risks)
• Negligence — the manufacturer failed to exercise reasonable care in testing, monitoring, and communicating the safety profile of the drug

What Makes Bowel Obstruction Claims Strong

• Emergency medical treatment — hospitalization, nasogastric tube placement, IV fluids, and NPO (nothing by mouth) status document the severity
• Surgical intervention — cases requiring surgery (exploratory laparotomy, bowel resection, colostomy) are particularly strong
• Objective imaging — CT scans, X-rays, and other imaging showing the obstruction provide undeniable evidence
• Clear timeline — onset of obstruction during active GLP-1 use creates a strong temporal connection
• No alternative explanation — absence of other common causes (prior surgery adhesions, hernias, tumors) strengthens the causation argument

Medical Evidence You Need

For a bowel obstruction claim, gather the following:

• Emergency department records — documenting your presentation, symptoms, and initial diagnosis
• Imaging studies — CT scan or abdominal X-ray showing the obstruction
• Hospitalization records — admission notes, daily progress notes, treatment orders
• Surgical records — if surgery was performed, the operative report detailing what was found and what procedures were done
• Pathology reports — if tissue was removed, the pathologist’s findings
• Prescription records — documentation of your GLP-1 drug use
• Post-discharge records — follow-up care, complications, and recovery documentation

Recovery and Long-Term Effects

Bowel obstruction recovery can be lengthy and challenging:

• Hospital stays can range from several days to weeks, depending on the severity and whether surgery was required
• Surgical recovery after bowel resection involves dietary restrictions, activity limitations, and gradual return to normal function over weeks to months
• Risk of recurrence — patients who have had one bowel obstruction are at increased risk of future episodes, particularly if adhesions form after surgery
• Dietary changes — many patients must adopt long-term dietary modifications to reduce the risk of recurrence
• Stoma care — if a temporary or permanent colostomy was required, the patient faces significant lifestyle adjustments
• Psychological impact — the trauma of a life-threatening emergency and the fear of recurrence can cause anxiety, depression, and PTSD

These long-term effects are compensable in the litigation and contribute to the overall value of a bowel obstruction claim.

Frequently Asked Questions

How common is bowel obstruction from GLP-1 drugs?

While bowel obstruction is less common than gastroparesis in GLP-1 users, it is well-documented in adverse event reports and clinical literature. The exact incidence rate is difficult to determine because adverse event reporting is voluntary, meaning the true number of cases is likely higher than reported figures suggest.

Can bowel obstruction be fatal?

Yes. Untreated or delayed-treatment bowel obstruction can lead to intestinal perforation, peritonitis, sepsis, and death. This is one reason why bowel obstruction claims carry significant weight in the litigation — the injury is not just serious, it is potentially life-threatening.

What if I had a partial obstruction that resolved without surgery?

Partial obstructions that were treated conservatively (with hospitalization, bowel rest, and IV fluids) may still qualify as a legal claim. The key is that you received medical treatment for the obstruction. Cases requiring surgical intervention are generally stronger, but any obstruction requiring hospitalization is a serious medical event.

Can I file a claim for bowel obstruction if I also have gastroparesis?

Yes. Multiple injuries from the same drug strengthen your overall case. Both bowel obstruction and gastroparesis are recognized qualifying injuries in the GLP-1 litigation, and experiencing both demonstrates the severity of the drug’s impact on your gastrointestinal system.

What should I do if I am currently experiencing symptoms?

Seek emergency medical care immediately. Bowel obstruction symptoms — severe abdominal pain, inability to pass gas or stool, vomiting, and abdominal swelling — require urgent evaluation. Your health is the priority. Legal considerations can be addressed after you are medically stable.

Take the Next Step

Bowel obstruction from GLP-1 drugs is a severe, potentially life-threatening injury that no patient should have to endure without accountability from the manufacturers. If you or a loved one was hospitalized for bowel obstruction after taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication, you may be entitled to significant compensation for your suffering, medical expenses, and ongoing effects.

If you’ve been affected, request a free case review today.

Advertisement. This content is provided for informational purposes only and does not constitute legal advice. NuLegal | Ashkaan Hassan, Esq. | CA Bar #283629